Visual Abstract

Glycemic change from baseline to 1-year was examined during the first year of LANDMARC, a 3-year prospective observational study (CTRI/2017/05/008452), which included patients with type 2 diabetes (T2D) taking ≥2 antihyperglycemic medications (with/without glycemic control). Out of 6236 patients (mean baseline values - age: 52.1 years, T2D duration: 8.6 years and A1C: 8.05%) enrolled, 5654 completed 1-year follow-up visit. All glycemic parameters improved significantly (p<0.0001) from baseline (A1C: -0.45% [1.53]; FPG: -12.17 mg/dL [53.33]; and PPG -17.61 mg/dL [76.49] (Table). Among A1C subgroups, the number of patients in the 7-7.9% group increased whereas those in other A1C subgroups (with high A1C) decreased; however, only 20% achieved optimum glycemic control (A1C<7%) (Table). Subgroups with cardiovascular risk factors, microvascular and macrovascular complications had suboptimal glycemic control (A1C>7%). In the first year of the LANDMARC study, though there was marked improvement in all glycemic parameters, a large majority of the patients remained uncontrolled, emphasizing the need for optimum diabetes management in India.

graphic
View largeDownload slide
Disclosure

S. Joshi: Advisory Panel; Self; Abbott, AstraZeneca, Biocon, Franco Indian, Glenmark, Lupin, Marico, Roche, Twinhealth, Zydus, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk, Sanofi, Serdia Pharmaceuticals (India) Pvt. Ltd. R. Ghosh: Employee; Self; Sanofi. S. Krishnan: Employee; Self; Sanofi. A. Nair: Employee; Self; Sanofi. S. Mohanasundaram: Employee; Self; Sanofi. S. K. Menon: Employee; Self; Sanofi. V. Salvi: Employee; Self; Sanofi. D. Chodankar: Employee; Self; Sanofi. C. Trivedi: None. S. Wangnoo: None. A. H. Zargar: None. A. K. Das: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Roche Pharma, Sanofi. N. Rais: None. K. Kumar: Advisory Panel; Self; Sanofi-Aventis. A. Mithal: Advisory Panel; Self; Eris Lifesciences Limited, Consultant; Self; Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals, Inc., USV Private Limited, Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Novo Nordisk, Sanofi. S. Kalra: Speaker’s Bureau; Self; Eli Lilly and Company, Novo Nordisk, Sanofi. A. Unnikrishnan: Advisory Panel; Self; Sanofi-Aventis, Other Relationship; Self; Novo Nordisk A/S, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes. H. Thacker: None. B. Sethi: None. S. Chowdhury: None.

Funding

Sanofi

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.